Browse ENAM

Summary
SymbolENAM
Nameenamelin
Aliases AIH2; amelogenesis imperfecta 2, hypocalcification (autosomal dominant); ADAI; AI1C
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix
Domain PF15362 Enamelin
Function

Involved in the mineralization and structural organization of enamel. Involved in the extension of enamel during the secretory stage of dental enamel formation.

> Gene Ontology
 
Biological Process GO:0002065 columnar/cuboidal epithelial cell differentiation
GO:0022604 regulation of cell morphogenesis
GO:0031214 biomineral tissue development
GO:0034505 tooth mineralization
GO:0036305 ameloblast differentiation
GO:0042475 odontogenesis of dentin-containing tooth
GO:0042476 odontogenesis
GO:0042481 regulation of odontogenesis
GO:0042482 positive regulation of odontogenesis
GO:0042487 regulation of odontogenesis of dentin-containing tooth
GO:0042488 positive regulation of odontogenesis of dentin-containing tooth
GO:0070166 enamel mineralization
GO:0070167 regulation of biomineral tissue development
GO:0070169 positive regulation of biomineral tissue development
GO:0070170 regulation of tooth mineralization
GO:0070172 positive regulation of tooth mineralization
GO:0070173 regulation of enamel mineralization
GO:0070175 positive regulation of enamel mineralization
GO:0097186 amelogenesis
GO:2000027 regulation of organ morphogenesis
Molecular Function GO:0005201 extracellular matrix structural constituent
GO:0030021 extracellular matrix structural constituent conferring compression resistance
GO:0030345 structural constituent of tooth enamel
Cellular Component GO:0005578 proteinaceous extracellular matrix
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolENAM
Nameenamelin
Aliases AIH2; amelogenesis imperfecta 2, hypocalcification (autosomal dominant); ADAI; AI1C
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ENAM and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolENAM
Nameenamelin
Aliases AIH2; amelogenesis imperfecta 2, hypocalcification (autosomal dominant); ADAI; AI1C
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ENAM in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolENAM
Nameenamelin
Aliases AIH2; amelogenesis imperfecta 2, hypocalcification (autosomal dominant); ADAI; AI1C
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ENAM in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1910.715
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1160.928
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2880.85
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2370.747
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0720.965
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.280.85
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.7160.216
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.630.427
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.6920.0223
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ENAM in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.15.55.60.384
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.16.84.30.673
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211723.85.917.90.197
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131138.59.129.40.166
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382713.27.45.80.69
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221318.215.42.81
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolENAM
Nameenamelin
Aliases AIH2; amelogenesis imperfecta 2, hypocalcification (autosomal dominant); ADAI; AI1C
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ENAM. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolENAM
Nameenamelin
Aliases AIH2; amelogenesis imperfecta 2, hypocalcification (autosomal dominant); ADAI; AI1C
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ENAM. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ENAM.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolENAM
Nameenamelin
Aliases AIH2; amelogenesis imperfecta 2, hypocalcification (autosomal dominant); ADAI; AI1C
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ENAM. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolENAM
Nameenamelin
Aliases AIH2; amelogenesis imperfecta 2, hypocalcification (autosomal dominant); ADAI; AI1C
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ENAM expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolENAM
Nameenamelin
Aliases AIH2; amelogenesis imperfecta 2, hypocalcification (autosomal dominant); ADAI; AI1C
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ENAM and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolENAM
Nameenamelin
Aliases AIH2; amelogenesis imperfecta 2, hypocalcification (autosomal dominant); ADAI; AI1C
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ENAM collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.